Dextromethorphan Abuse Reduction Act of 2007

House Bill and S.3230, Dept. of Labor, HHS, and Education, and Related Agencies Appropriations Act of 2009 (All provisions related to the NIAAA, NIDA, SAMHSA and all provisions related to the Safe and Drug Free Schools and Communities Program); House and Senate Bills, Department of Defense Appropriations Act, 2009 (all provisions related to counter-drug activities); House Bill and S.3260, Financial Services and General Government Appropriations Act, 2009 (all provisions related to the Office of National Drug Control Policy); House Bill and S.3182, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2009 (all provisions related to the Weed and Seed Program Fund); House Bill and S.3288, Department of State, Foreign Operations, and Related Programs Appropriations Act, 2009 (all provisions related to the International Narcotics and Law Enforcement Demand Reduction Program); H.R. 1424 Paul Wellstone Mental Health and Addiction Equity Act of 2007; House and Senate Bills, No Child Left Behind Reauthorization, all provisions related to the State Grants portion of the Safe and Drug Free Schools and Communities Program; House and Senate Bills, Substance Abuse and Mental Health Services Modernization Act; S. 2237, Crime Control and Prevention Act of 2007; H.R. 6486, the Drug Test Integrity Act of 2008; S.2274, the Dextromethorphan Abuse Reduction Act of 2007

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, State, Dept of (DOS)

FDA reform proposals; Pseudoephedrine H.R. 970 DXM Distribution Act S. 1378 DXM Distribution Act S. 2274 Dextromethorphan Abuse Reduction Act Monograph System Reform Proposal S. 2274 DXM Abuse Reduction Act

Client expense: $1,047,210 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Security Agency (NSA), Natl Security Council (NSC), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office

-H.R. 1424, "Paul Wellstone Mental Health and Addiction Equity Act of 2007," regarding amending section 712 of the Employee Retirement Income Security Act of 1974, section 2705 of the Public Health Service Act, and section 9812 of the Internal Revenue Code of 1986 to require equity in the provision of mental health and substance-related disorder benefits under group health plans; -H.R. 1494 / S. 830, "Pediatric Medical Device Safety and Improvement Act of 2007," regarding improving the process for the development of needed pediatric medical devices; -H.R. 1956, "Patient Protection and Innovative Biologic Medicines Act of 2007," regarding amending the public Health Service Act to provide for the approval of similar biological products; -H.R. 2193, "Animal Protection Accountability Improvement Act," regarding amending the Animal Welfare Act to increase the penalties for violations of such Act to prohibit the use of animals for marketing medical devices; -H.R. 2349/ S. 1413, "Uterine Fibroid Research and Education Act of 2007," regarding providing for research and education with respect to uterine fibroids; -H.R. 3333 / S. 1576, "Minority Health Improvement and Health Disparity Elimination Act," regarding amending the Public Health Services Act to improve the health and healthcare of racial and ethnic minority groups; -H.R. 788 / S. 468, "Food and Drug Administration Safety Act of 2007," regarding amending the Federal Food, Drug, and Cosmetic Act with respect to drug safety; -H.R. 2900, "Food and Drug Administration Amendments Act of 2007," regarding amending the Federal Food, Drug, and Cosmetic Act to revise and extend the use-fee programs for prescription drugs and for medical devices and to enhance the postmarket authorities of the Food and Drug Administration with respect to the safety of drugs; -S. 1082, "Food and Drug Administration Revitalization Act," regarding amending the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act to reauthorize drug and device user fees and ensure the safety of medical products; -S. 1695, "Biologics Price Competition and Innovation Act of 2007," regarding amending the Public Health Service Act to establish a pathway for the licensure of biosilimar products to promote innovation in the life sciences; -S. 467, "Fair Access to Clinical Trials Act of 2007 or the 'FACT Act'," regarding amending the Public Health Services Act to expand clinical trials drug data bank; -S. 558, "Mental Health Parity Act of 2007," regarding all provisions ; -S. 628, "Critical Access to Health Information Technology Act of 2007," regarding improving grants for rural health information technology development activities; -S. 993, "Pediatric Research Improvement Act," regarding improving pediatric research; issues regarding Acetemorphine and Phenelyperine; -H.R. 3580, "Food and Drug Administration Amendments Act of 2007," regarding fees related to prescription drugs, medical devices, and food safety; -H.R. 2419 / S. 2302, "Food and Energy Security Act of 2007," regarding marketing and financial assistance related to farming and food production; -H.R. 5606 / S. 2029, "Physician Payments Sunshine Act of 2007," regarding amending Title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, or medical supplies for which payment is made under Medicare, Medicaid, or SCHIP; -S. 2221, "Transparency in Medical Device Pricing Act of 2007," regarding amending Title XVIII of the Social Security Act to provide for the reporting of sales price data for implantable devices; -H.R. 3043, "Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008," regarding appropriations for the Department of Health and Human Services; -H.R. 5629, "Pathway for Biosimilar Act," regarding amending the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products; -H.R. 5839, "Safeguarding America's Pharmaceuticals Act of 2008", To Amend the Federal Food, Drug, and Cosmetic Act to improve the safety of drugs, regarding all provisions; -S. 334, "Healthy Americans Act", A bill to provide affordable, guaranteed private health coverage that will make Americans healthier and can never be taken away, regarding all provisions; -H.R. 6381, "Medical Device Safety Act of 2008", To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices, regarding all provisions; -S. 438, "Fair Prescription Drug Competition Act", A bill to amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs, regarding all provisions; -S.2274, "A bill to amend the Controlled Substances Act to prevent the abuse of dextromethorphan", and for other purposes, regarding all provisions. -S.3409 "A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety and quality of medical products and enhance the authorities of the Food and Drug Administration", and for other purposes; regarding all provisions. -S.1378 "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan", and for other purposes; regarding all provisions. -S. 3408, "Comparative Effectiveness Research Act of 2008", A bill to amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes, regarding all provisions; -S. 1276, "Methamphetamine Production Prevention Act of 2008", A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices, regarding all provisions. -Proposed Rule (CMS-1403-P), Regarding revisions to Amendment of the E-Prescribing Exemption for Computer Generated Facsimile Transmissions; -S.2424, "A bill to ensure that all Americans have basic health literacy skills to function effectively as patients and health care consumers", regarding all provisions.

-S. 635, "Methamphetamine Remediation Research Act of 2007," regarding providing for a research program for remediation of closed methamphetamine production laboratories; issues regarding Federal judicial salaries; -S. 2274, "Dextromethorphan Abuse Reduction Act of 2007", A bill to amend the Controlled Substances Act to prevent the abuse of dextromethorphan, and for other purposes, regarding all provisions; -S. 1378, "Dextromethorphan Distribution Act of 2007", A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan, and for other purposes; -S. 1276, "Methamphetamine Production Prevention Act of 2008 ", A bill to establish a grant program to facilitate the creation of methamphetamine precursor electronic logbook systems, and for other purposes, regarding all provisions. -S.2071, "A bill to enhance the ability to combat methamphetamine", regarding all provisions.

Client expense: $1,440,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Follow-on Biologics Judicial Pay Controlled substances Pre-emption; legal reform S.1695-Biologics Price Competition and Innovation Act of 2007 S.1638-Federal Judicial Salary Restoration Act of 2007 H.R.3753-Federal Judicial Salary Restoration Act of 2007 S.1276-Methamphetamine Production Prevention Act of 2007 S.2274-Dextromethorphan Abuse Reduction Act of 2007 S.2450-To amend the Federal Rules of Evidence to address the waiver of the attorney-client privilege and the work product doctrine

Client expense: Not reported · Firm income: $90,000

Follow-on Biologics Judicial Pay Controlled substances Pre-emption; legal reform S.1695-Biologics Price Competition and Innovation Act of 2007 S.1638-Federal Judicial Salary Restoration Act of 2007 H.R.3753-Federal Judicial Salary Restoration Act of 2007 S.1276-Methamphetamine Production Prevention Act of 2007 S.2274-Dextromethorphan Abuse Reduction Act of 2007 S.2450-To amend the Federal Rules of Evidence to address the waiver of the attorney-client privilege and the work product doctrine

Client expense: Not reported · Firm income: $90,000

S. 2274, Dextromethorphan Abuse Reduction Act of 2007, proposed scheduling of unfinished Dextromethophan as a Schedule V product under the Controlled Substances Act and mandates restriction for the sale of retail products which contain Dextromethorphan. S.2237, Crime Control and Prevention Act of 2007, Subtitle B containing the same provisions as in the Dextromethorphan Abuse Reduction Act of 2007.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.970, the Dextromethorphan Distribution Act, as related to the abuse of dextromethorphan. H.R.971, the Community Pharmacy Fairness Act, as related to provider negotiations in the Medicare program. H.R.1424, the Emergency Economic Stabilization Act of 2008, as related to fiscal sustainablity of healthcare services. H.R.1474, the Fair and Speedy Treatment (FAST) of Medicare Prescription Drug Claims Act, as related to provider reimbursement in the Medicare program. H.R.3700, the Fair Medicaid Drug Payment Act, as related to pharmacy reimbursement in the Medicaid program. H.R.5613, Protecting the Medicaid Safety Net Act of 2008, as related to provider participation in the Medicaid program. H.R.5839, Safeguarding America's Pharmaceuticals Act of 2008, as related to drug safety and electronic tracking of pharmaceuticals. H.R.6353/S.980, Ryan Haight Online Pharmacy Consumer Protection Act of 2008, as related to online pharmacies. H.R.6357, PRO(TECH)T Act of 2008, as related to pharmacy involvement in health information technology. H.R. 6898, the Health-e Information Technology Act of 2008 as related to pharmacy involvement in health information technology H.R. 7110, the Job Creation and Unemployment Relief Act of 2008, as related to increased funding for state Medicaid programs. S.484, the Enhancing Drug Safety and Innovation Act, all provisions related to the safety of prescription medicines. S. 1276, the Methamphetamine Production Prevention Act as related to recordkeeping requirements for pharmacies. S.1693, Wired for Health Care Quality Act, as related to health information technology. S.1827, Pharmacists Access and Recognition in Medicare (PhARM) Act, as related to provider participation in the Medicare program. S.1915, Electronic Prescribing Drug Act, as related to the regulation of electronic prescribing of pharmaceuticals. S.1951, the Fair Medicaid Drug Payment Act, as related to pharmacy reimbursement in the Medicaid program. S.1954, Pharmacy Access Improvement (PhAIm) Act, as related to access standards to pharmacies. S.2013/H.R.390, Patient and Pharmacy Protection Act, as related to prescription requirements in the Medicaid program. S.2071, Combat Methamphetamine Enhancement Act, as related to the distribution of legal substances used in the production of methamphetamine. S.2274, Dextromethorphan Abuse Reduction Act, as related to the abuse of dextromethorphan. S.2408/H.R.4296, Medicare Electronic Medication and Safety Protection (E-MEDS) Act of 2007, as related to electronic health care in the Medicare program. S.3101/H.R.6331, Medicare Improvements for Patients and Providers Act of 2008, as related to pharmacy reimbursement in the Medicaid and Medicare programs and electronic health care. Various issues related to the disposal of prescription drugs and drug Take Back programs, no specific legislation

FDA reform proposals; Pseudoephedrine H.R. 970 DXM Distribution Act S. 1378 DXM Distribution Act S. 2274 Dextromethorphan Abuse Reduction Act Monograph System Reform Proposal S. 2274 DXM Abuse Reduction Act

Client expense: $756,650 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Security Agency (NSA), Natl Security Council (NSC), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office

-S. 635, "Methamphetamine Remediation Research Act of 2007," regarding providing for a research program for remediation of closed methamphetamine production laboratories; issues regarding Federal judicial salaries; -S. 2274, "Dextromethorphan Abuse Reduction Act of 2007", A bill to amend the Controlled Substances Act to prevent the abuse of dextromethorphan, and for other purposes, regarding all provisions; -S. 1378, "Dextromethorphan Distribution Act of 2007", A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan, and for other purposes; -S. 1276, "Methamphetamine Production Prevention Act of 2008 ", A bill to establish a grant program to facilitate the creation of methamphetamine precursor electronic logbook systems, and for other purposes, regarding all provisions.

Client expense: $1,500,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Pharmacy Issues related to the sale of food and drugs, drug safety and drug abuse. HR 5839, To amend the Federal Food, Drug, and Cosmetic Act to improve the safety of drugs. HR 3610, Food and Drug Import Safety Act of 2007 S. 2071, Combat Methamphetamine Enhancement Act of 2007 S. 1276, Methamphetamine Production Prevention Act of 2007 HR 4911, Human Growth Hormone Restriction Act of 2007 S 877, Controlling the Abuse of Prescriptions Act of 2007 S. 2274, Dextromethorphan Abuse Reduction Act of 2007 S. 654, Safe Food Act of 2007 H.R. 1148, Safe Food Act of 2007 HR 5904, Safe FEAST Act of 2008 S. 3666 and HR 6831, Copper Theft Prevention Act of 2008 HR 5546, Credit Card Fair Fee Act

Client expense: $1,316,532 · Firm income: Not reported

S.1276/H.R. 2747 Methamphetamine Production Prevention Act of 2007 regarding electronic logbooks and tracking systems for pseudoephedrine; H.R. 3610 Food and Drug Import Safety Act of 2007 Sec. 6 regarding country of origin labeling for drugs and devices; S. 2274 Dextromethrophan Abuse Reduction Act of 2007 regarding amending the Controlled Substances Act to prevent the abuse of DXM, limiting sales to those over the age of 18; S. 2274 Dextromethrophan Abuse Reduction Act of 2007 regarding amending the Controlled Substances Act to prevent the abuse of DXM, limiting sales to those over the age of 18; S. 2045 the Consumer Product Safety Commission Reform Act of 2007 Sec. 23 (e) regarding the implementation of new lead standards.

Client expense: $320,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

House Bill and S.3230, Dept. of Labor, HHS, and Education, and Related Agencies Appropriations Act of 2009 (All provisions related to the NIAAA, NIDA, SAMHSA and all provisions related to the Safe and Drug Free Schools and Communities Program); House and Senate Bills, Department of Defense Appropriations Act, 2009 (all provisions related to counter-drug activities); House Bill and S.3260, Financial Services and General Government Appropriations Act, 2009 (all provisions related to the Office of National Drug Control Policy); House Bill and S.3182, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2009 (all provisions related to the Weed and Seed Program Fund); House Bill and S.3288, Department of State, Foreign Operations, and Related Programs Appropriations Act, 2009 (all provisions related to the International Narcotics and Law Enforcement Demand Reduction Program); H.R. 1424 Paul Wellstone Mental Health and Addiction Equity Act of 2007; House and Senate Bills, No Child Left Behind Reauthorization, all provisions related to the State Grants portion of the Safe and Drug Free Schools and Communities Program; House and Senate Bills, Substance Abuse and Mental Health Services Modernization Act; S. 2237, Crime Control and Prevention Act of 2007; H.R. 6486, the Drug Test Integrity Act of 2008; S.2274, the Dextromethorphan Abuse Reduction Act of 2007

Client expense: Not reported · Firm income: Not reported

See addendum. H.R.970, the Dextromethorphan Distribution Act, as related to the abuse of dextromethorphan. H.R.971, the Community Pharmacy Fairness Act, as related to provider negotiations in the Medicare program. H.R.1108, Family Smoking Prevention and Tobacco Control Act, as related to the regulation of the sale of tobacco products. H.R.1424, the Emergency Economic Stabilization Act of 2008, as related to fiscal sustainablity for healthcare services. H.R.1474, the Fair and Speedy Treatment (FAST) of Medicare Prescription Drug Claims Act, as related to provider reimbursement in the Medicare program. H.R.3700, the Fair Medicaid Drug Payment Act, as related to pharmacy reimbursement in the Medicaid program. H.R.4008, Credit and Debit Card Receipt Clarification Act of 2007, as related to fair credit card practices. H.R.5491, Emilys Act, as related to the certification of pharmacy technicians. H.R.5546, Credit Card Fair Fee Act of 2008, as related to fair credit card practices. H.R.5613, Protecting the Medicaid Safety Net Act of 2008, as related to provider participation in the Medicaid program. H.R.5658, Duncan Hunter National Defense Authorization Act for Fiscal Year 2009, as related to provider participation in the TRICARE program. H.R.5839, Safeguarding America's Pharmaceuticals Act of 2008, as related to drug safety and electronic tracking of pharmaceuticals. H.R.6353/S.980, Ryan Haight Online Pharmacy Consumer Protection Act of 2008, as related to online pharmacies. H.R.6357, PRO(TECH)T Act of 2008, as related to pharmacy involvement in health information technology. H.R. 6491/S.3434, the Organized Retail Crime Act of 2008, as related to the prosecution of organized theft. H.R. 6713, the E-Fencing Enforcement Act of 2008, as related to the prosecution of organized theft. H.R. 6831/S.3666, the Copper Theft Prevention Act of 2008 as related to theft and interstate fencing of stolen copper. H.R. 6898, the Health-e Information Technology Act of 2008 as related to pharmacy involvement in health information technology H.R. 7110, the Job Creation and Unemployment Relief Act of 2008, as related to increased funding for state Medicaid programs. S.484, the Enhancing Drug Safety and Innovation Act, all provisions related to the safety of prescription medicines. S. 1276, the Methamphetamine Production Prevention Act as related to recordkeeping requirements for pharmacies. S.1693, Wired for Health Care Quality Act, as related to health information technology. S.1827, Pharmacists Access and Recognition in Medicare (PhARM) Act, as related to provider participation in the Medicare program. S.1915, Electronic Prescribing Drug Act, as related to the regulation of electronic prescribing of pharmaceuticals. S.1951, the Fair Medicaid Drug Payment Act, as related to pharmacy reimbursement in the Medicaid program. S.1954, Pharmacy Access Improvement (PhAIm) Act, as related to access standards to pharmacies. S.2013/H.R.390, Patient and Pharmacy Protection Act, as related to prescription requirements in the Medicaid program. S.2071, Combat Methamphetamine Enhancement Act, as related to the distribution of legal substances used in the production of methamphetamine. S.2274, Dextromethorphan Abuse Reduction Act, as related to the abuse of dextromethorphan. S.2408/H.R.4296, Medicare Electronic Medication and Safety Protection (E-MEDS) Act of 2007, as related to electronic health care in the Medicare program. S.2978, Credit and Debit Card Receipt Clarification Act of 2008, as related to fair credit card practices S.3001, National Defense Authorization Act for Fiscal Year 2009, as related to provider participation in the TRICARE program. S.3086, Credit Card Fair Fee Act of 2008, as related to fair credit card practices. S.3101/H.R.6331, Medicare Improvements for Patients and Providers Act of 2008, as related to pharmacy reimbursement in the Medicaid and Medicare programs and electronic health care.

Dextromethorphan Abuse, Methamphetamine S. 2237, S. 2274, S. 1378, HR 970, S. 1276

Client expense: $116,217 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

Follow-on Biologics Judicial Pay Controlled substances Pre-emption; legal reform S.1695-Biologics Price Competition and Innovation Act of 2007 S.1638-Federal Judicial Salary Restoration Act of 2007 H.R.3753-Federal Judicial Salary Restoration Act of 2007 S.1276-Methamphetamine Production Prevention Act of 2007 S.2274-Dextromethorphan Abuse Reduction Act of 2007 S.2450-To amend the Federal Rules of Evidence to address the waiver of the attorney-client privilege and the work product doctrine

Client expense: Not reported · Firm income: $90,000

Follow-on Biologics Judicial Pay Controlled substances Pre-emption; legal reform S.1695-Biologics Price Competition and Innovation Act of 2007 S.1638-Federal Judicial Salary Restoration Act of 2007 H.R.3753-Federal Judicial Salary Restoration Act of 2007 S.1276-Methamphetamine Production Prevention Act of 2007 S.2274-Dextromethorphan Abuse Reduction Act of 2007 S.2450-To amend the Federal Rules of Evidence to address the waiver of the attorney-client privilege and the work product doctrine

Client expense: Not reported · Firm income: $90,000

HR 6337, Protecting Records, Optimizing Treatment, and Easing Communication through Healthcare Technology Act of 2008 - Title III, Privacy and Security Provisions - would require a patient's written consent before using their health information for certain purposes. HR 6331Medicare Patients and Providers Improvement Act - AMP - Provisions relating to retail pharmacy and Medicaid drug reimbursement (became public law 7/15/08) HR 5839, Safeguarding America's Pharmaceuticals Act - E-Pedigree mandates, enhanced wholesaler licensing, national uniform standards HR 970 and S. 2274, Dextromethorphan Distribution Act of 2007- prohibits sale of DXM products to persons under 18 years of age. HR 6898, Health-e Information Technology Act of 2008, Title IV, Privacy and Security Provisions - allows pharmacies to use protected health information for treatment, payment and healthcare operations.

Client expense: $1,600,130 · Firm income: Not reported

S. 2274, Dextromethorphan Abuse Reduction Act of 2007, proposed scheduling of unfinished Dextromethophan as a Schedule V product under the Controlled Substances Act and mandates restriction for the sale of retail products which contain Dextromethorphan. S.2237, Crime Control and Prevention Act of 2007, Subtitle B containing the same provisions as in the Dextromethorphan Abuse Reduction Act of 2007.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

FDA reform proposals; Pseudoephedrine H.R. 970 DXM Distribution Act S. 1378 DXM Distribution Act S. 2274 Dextromethorpha Abuse Reduction Act Monograph System Reform Proposal S. 2274 DXM Abuse Reduction Act

Client expense: $801,472 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Security Agency (NSA), Natl Security Council (NSC), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office

House Bill and S.3230, Dept. of Labor, HHS, and Education, and Related Agencies Appropriations Act of 2009 (All provisions related to the NIAAA, NIDA, SAMHSA and all provisions related to the Safe and Drug Free Schools and Communities Program); House and Senate Bills, Department of Defense Appropriations Act, 2009 (all provisions related to counter-drug activities); House Bill and S.3260, Financial Services and General Government Appropriations Act, 2009 (all provisions related to the Office of National Drug Control Policy); House Bill and S.3182, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2009 (all provisions related to the Weed and Seed Program Fund); House Bill and S.3288, Department of State, Foreign Operations, and Related Programs Appropriations Act, 2009 (all provisions related to the International Narcotics and Law Enforcement Demand Reduction Program); H.R. 1424 Paul Wellstone Mental Health and Addiction Equity Act of 2007; House and Senate Bills, No Child Left Behind Reauthorization, all provisions related to the State Grants portion of the Safe and Drug Free Schools and Communities Program; House and Senate Bills, Substance Abuse and Mental Health Services Modernization Act; S. 2237, Crime Control and Prevention Act of 2007; the Drug Test Subversion Act (unnumbered House bill); S.2274, Dextromethorphan Abuse Reduction Act of 2007

Client expense: Not reported · Firm income: Not reported

Pharmacy Issues related to the sale of food and drugs, drug safety and drug abuse. HR 5839, To amend the Federal Food, Drug, and Cosmetic Act to improve the safety of drugs.; HR 3610, Food and Drug Import Safety Act of 2007; S. 2071, Combat Methamphetamine Enhancement Act of 2007; S. 1276, Methamphetamine Production Prevention Act of 2007; HR 4911, Human Growth Hormone Restriction Act of 2007; S 877, Controlling the Abuse of Prescriptions Act of 2007; S. 2274, Dextromethorphan Abuse Reduction Act of 2007; S. 654, Safe Food Act of 2007 H.R. 1148, Safe Food Act of 2007 HR 5904 Safe FEAST Act of 2008

Client expense: $1,010,101 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

Dextromethorphan Abuse S. 2237, S. 2274, S. 1378, H.R. 970

Client expense: $110,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

Dextromethorphan Abuse, Methamphetamine S. 2237, S. 2274, S. 1378, H.R. 970, S. 1276

Client expense: $150,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

S.1951 and HR 3700, Fair Medicaid Drug Payment Act of 2007, AMP - Provisions relating to retail pharmacy and Medicaid drug reimbursement. S. 3101, Medicare Improvement for Patients and Providers Act, AMP - Provisions relating to retail pharmach and Medicaid drug reimbrusement HR 6331Medicare Patients and Providers Improvement Act, - AMP - Provisions relating to retail pharmacy and Medicaid drug reimbursement HR 5839, Safeguarding America's Pharmaceuticals Act -- E-Pedigree mandates, enhanced wholesaler licensing, national uniform standards HR 970 and S. 2274, Dextromethorphan Distribution Act of 2007, -- prohibits sale of DXM products to persons under 18 years of age

Client expense: $1,708,000 · Firm income: Not reported

S. 1276/H.R. 2747 the "Methamphetamine Production Prevention Act of 2007" - electronic logbooks, tracking systems; H.R. 3610 the "Food and Drug Import Safety Act of 2007" - Sec. 6 regarding country of origin labeling for drugs and devices; S. 2274 the "Dextromethrophan Abuse Reduction Act of 2007" - regarding amending the Controlled Substances Act to prevent the abuse of DXM, limiting sales to those over the age of 18; S. 2045 the "Consumer Product Safety Commission Reform Act of 2007" - Sec. 23 (e) regarding the implementation of new lead standards; S. 1693 the "Wired for Healthcare Quality Act of 2007" Title IV, Sec 401 Privacy and Security regarding changes in the definition of marketing under HIPAA and breach notification; House HIT discussion draft regarding changes to the definition of marketing under HIPAA, breach notification and accounting of electronic disclosures.

Client expense: $310,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

S. 635, "Methamphetamine Remediation Research Act of 2007," regarding providing for a research program for remediation of closed methamphetamine production laboratories; issues regarding Federal judicial salaries; S. 2274, "A bill to amed the Controlled Substances Act to prevent the abuse of dextromethorphan, and for other purposes", regarding all provisions; S. 1378, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan, and for other purposes; S. 1276, "A bill to establish a grant program to facilitate the creation of methamphetamine precursor electronic logbook systems, and for other purposes", regarding all provisions.

Client expense: $1,700,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

See addendum. H.R.970, the Dextromethorphan Distribution Act, as related to the abuse of dextromethorphan. H.R.971, the Community Pharmacy Fairness Act, as related to provider negotiations in the Medicare program. H.R.1038/S.623, Access to Life-Saving Medicine Act, as related to the approval of generic biopharmaceuticals. H.R.1108, Family Smoking Prevention and Tobacco Control Act, as related to the regulation of the sale of tobacco products. H.R.1474, the Fair and Speedy Treatment (FAST) of Medicare Prescription Drug Claims Act, as related to provider reimbursement in the Medicare program. H.R.3140, Saving Our Community Pharmacies Act, as related to Medicaid provider reimbursement. H.R.3193, Access to Community Pharmacy Preservation Act, as related to Medicaid provider reimbursement. H.R.3700, the Fair Medicaid Drug Payment Act, as related to pharmacy reimbursement in the Medicaid program. H.R.4008, Credit and Debit Card Receipt Clarification Act of 2007, as related to fair credit card practices. H.R.5491, Emilys Act, as related to the certification of pharmacy technicians. H.R.5546, Credit Card Fair Fee Act of 2008, as related to fair credit card practices. H.R.5613, Protecting the Medicaid Safety Net Act of 2008, as related to provider participation in the Medicaid program. H.R.5629, Pathway for Biosimilars Act, as related to the availability of generic pharmaceuticals. H.R.5658, Duncan Hunter National Defense Authorization Act for Fiscal Year 2009, as related to provider participation in the TRICARE program. H.R.5839, Safeguarding America's Pharmaceuticals Act of 2008, as related to drug safety and electronic tracking of pharmaceuticals. H.R.6252, Medicare DMEPOS Competitive Acquisition Reform Act of 2008, as related to provider participation in the Medicare competitive bidding program. H.R.6331, the Medicare Improvements for Patients and Providers Act of 2008, as related to pharmacy reimbursement, electronic health care, and Medicare programs. H.R.6353, Ryan Haight Online Pharmacy Consumer Protection Act of 2008, as related to online pharmacies. H.R.6357, PRO(TECH)T Act of 2008, as related to health information technology. S.484, the Enhancing Drug Safety and Innovation Act, all provisions related to the safety of prescription medicines. S.980, Ryan Haight Online Pharmacy Consumer Protection Act of 2008, as related to online pharmacies. S.1693, Wired for Health Care Quality Act, as related to health information technology. S.1695, the Biologics Price Competition and Innovation Act, as related to the approval of generic biopharmaceuticals. S.1827, Pharmacists Access and Recognition in Medicare (PhARM) Act, as related to provider participation in the Medicare program. S.1915, Electronic Prescribing Drug Act, as related to the regulation of electronic prescribing of pharmaceuticals. S.1951, the Fair Medicaid Drug Payment Act, as related to pharmacy reimbursement in the Medicaid program. S.1954, Pharmacy Access Improvement (PhAIm) Act, as related to access standards to pharmacies. S.2013/H.R.390, Patient and Pharmacy Protection Act, as related to prescription requirements in the Medicaid program. S.2071, Combat Methamphetamine Enhancement Act, as related to the distributio of legal substances used in the production of methamphetamine. S.2274, Dextromethorphan Abuse Reduction Act, as related to the abuse of dextromethorphan. S.2408/H.R.4296, Medicare Electronic Medication and Safety Protection (E-MEDS) Act of 2007, as related to electronic health care in the Medicare program. S.2978, Credit and Debit Card Receipt Clarification Act of 2008, as related to fair credit card practices S.3001, National Defense Authorization Act for Fiscal Year 2009, as related to provider participation in the TRICARE program. S.3086, Credit Card Fair Fee Act of 2008, as related to fair credit card practices. S.3101, Medicare Improvements for Patients and Providers Act of 2008, as related to pharmacy reimbursement and electronic health care.

S. 2274, Dextromethorphan Abuse Reduction Act of 2007, proposed scheduling of unfinished Dextromethophan as a Schedule V product under the Controlled Substances Act and mandates restriction for the sale of retail products which contain Dextromethorphan. S. 2237, Crime Control and Prevention Act of 2007, Subtitle B containing the same provisions as in the Dextromethorphan Abuse Reduction Act of 2007.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 5839, To amend the Federal Food, Drug, and Cosmetic Act to improve the safety of drugs.; HR 3610, Food and Drug Import Safety Act of 2007; S. 2071, Combat Methamphetamine Enhancement Act of 2007; S. 1276, Methamphetamine Production Prevention Act of 2007; HR 4911, Human Growth Hormone Restriction Act of 2007; S 877, Controlling the Abuse of Prescriptions Act of 2007; S. 2274, Dextromethorphan Abuse Reduction Act of 2007; S. 654, Safe Food Act of 2007

Client expense: $928,643 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

HR 5839, To amend the Federal Food, Drug, and Cosmetic Act to improve the safety of drugs.; HR 3610, Food and Drug Import Safety Act of 2007; S. 2071, Combat Methamphetamine Enhancement Act of 2007; S. 1276, Methamphetamine Production Prevention Act of 2007; HR 4911, Human Growth Hormone Restriction Act of 2007; S 877, Controlling the Abuse of Prescriptions Act of 2007; S. 2274, Dextromethorphan Abuse Reduction Act of 2007; S. 654, Safe Food Act of 2007

Client expense: $928,643 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

S. 1276/H.R. 2747 the "Methamphetamine Production Prevention Act of 2007" - electronic logbooks, tracking systems; H.R. 3610 the "Food and Drug Import Safety Act of 2007" - Sec. 6 regarding country of origin labeling for drugs and devices; S. 2274 the "Dextromethrophan Abuse Reduction Act of 2007" - regarding amending the Controlled Substances Act to prevent the abuse of DXM, limiting sales to those over the age of 18; S. 2045 the "Consumer Product Safety Commission Reform Act of 2007" - Sec. 23 (e) regarding the implementation of new lead standards; H.R. 1108 the "Family Smoking Prevention and Tobacco Control Act" Title I, Chapter IX Sec. 913 regarding equal treatment of retail outlets and Sec 917 regarding preservation of state and local authority.

Client expense: $300,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

FDA reform proposals; Pseudoephedrine S. 1276 Methamphetamine Production Preventation Act of 2007 H.R. 970 DXM Distribution Act S. 1378 DXM Distribution Act DXM Abuse Monograph System Reform Proposal S. 2274 DXM Abuse Reduction Act H.R. 4083 Non-Prescription Drug modernization Act of 2007

Client expense: $697,236 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Security Agency (NSA), Natl Security Council (NSC), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office

See addendum. 1.S.242/H.R.380, the Pharmaceutical Market Access and Drug Safety Act of 2007, as related to provisions governing the importation of prescription drugs. 2.S.251, the Pharmaceutical Market Access Act of 2007, all provisions governing the importation of prescription drugs. 3.S. 484, the Enhancing Drug Safety and Innovation Act of 2007, all provisions related to the safety of prescription medicines. 4.S. 604, the Military Health Care Protection Act, as related to provider participation in the Department of Defense TRICARE program. 5.S. 980, Online Pharmacy Consumer Protection Act of 2007, as related to the regulation of online pharmacies. 6.S. 1200, Indian Health Care Improvement Act Amendments of 2007, all provisions related to reducing fraud and abuse in the Medicare program. 7.S. 1276/H.R.2747, the Methamphetamine Production Prevention Act of 2007, as related to the distribution of legal substances used in the production of methamphetamine. 8.S. 1693, the Wired for Health Care Quality Act of 2007, as related to improving health information technology. 9.S. 1695, the Biologics Price Competition and Innovation Act of 2007, as related to the approval of generic biopharmaceuticals. 10.S. 1827, Pharmacist Access and Recognition in Medicare (PhARM) Act of 2007 as related to provider participation in the Medicare program. 11.S.1915, Electronic Prescription Drug Act of 2007, as related to the regulation of electronic prescribing of pharmaceuticals 12.S.1951/H.R.3700, Fair Medicaid Drug Payment Act of 2007, as related to Medicaid provider reimbursement. 13.S.1954, Pharmacy Access Improvement (PhAIm) Act of 2007, as related to access standards to pharmacies. 14.S.2013/H.R.3090, Patient and Pharmacy Protection Act of 2007, as related to prescription requirements in the Medicaid program. 15.S.2071, Combat Methamphetamine Enhancement Act of 2007, as related to the distribution of legal substances used in the production of methamphetamine. 16.S.2274, Dextromethorphan Abuse Reduction Act of 2007, as related to steps to prevent the abuse of dextromethorphan. 17.S.2408/H.R.4296, Medicare Electronic Medication and Safety Protection (E-MEDS) Act of 2007, as related to the regulation of electronic prescribing of pharmaceuticals. 18.H.R.976, Small Business Tax Relief Act of 2007, all provisions associated with work-related tax credits. 19.H.R. 970, the Dextromethorphan Distribution Act of 2007, as related to steps to prevent the abuse of dextromethorphan. 20.H.R. 971/S.855, the Community Pharmacy Fairness Act of 2007, as related to provider negotiations in the Medicare program. 21.H.R.1038/S.623, Access to Life-Saving Medicine Act, as related to the approval of generic biopharmaceuticals. 22.H.R. 1474, the Fair and Speedy Treatment (FAST) of Medicare Prescription Drug Claims Act of 2007, as related to provider reimbursement in the Medicare program 23.H.R.1585/S.1548, National Defense Authorization Act for Fiscal Year 2008, as related to retail pharmacy participation in the Department of Defense TRICARE program. 24.H.R.1845, the Medicare Durable Medical Equipment Access Act of 2007, as related to provider inclusion in the Medicare Part B program. 25.H.R.1902, the Protecting Consumer Access to Generic Drugs Act of 2007, as related to the availability of generic pharmaceuticals. 26.H.R.2716, the Reducing Fraudulent and Imitation Drugs Act of 2007, as related to the safety of prescription drugs. 27.H.R. 2900, the Food and Drug Administration Amendments of 2007, all provisions related to prescription drug information and safety. 28.H.R.3109, the Dental Health Promotion Act of 2007, all provisions related to payment for health services. 29.H.R.3140, Saving Our Community Pharmacies Act of 2007, as related to Medicaid provider reimbursement. 30.H.R.3162, Children's Health and Medicare Protection Act of 2007, provisions related to health insurance in the Medicare program. 31.H.R.3193, Access to Community Pharmacy Preservation Act of 2007, as related to Medicaid provider reimbursement. 32.H.R.3580, Food and Drug Administration Amendments Act of 2007, all provisions related to prescription drug information and safety. 33.H.R.3610, Food and Drug Import Safety Act of 2007, provisions related to the safety of prescription drugs. 34.H.R.5268/S.2620, Temporary Increase of Medicaid FMAP, all provisions related to payments in the Medicaid program. 35.H.R.5480/S.2662, Medicare Funding Warning Response Act of 2008, all provisions related to provider access and payments in the Medicare program. 36.H.R.5491, Emilys Act, as related to the certification of pharmacy technicians. 37.H.R.5546, Credit Card Fair Fee Act of 2008, as related to fees associated with credit card purchase. 38.H.R.5613, Protecting the Medicaid Safety Net Act of 2008, all provisions related to provider participation in the Medicaid program. 39.H.R.5629, Pathway for Biosimilars Act, as related to the availability of generic pharmaceuticals. 40.H.Con.Res.312/S.Con.Res.70, Concurrent Resolution on the Budget for Fiscal Year 2009, all provisions related to healthcare providers and prescription drugs.

Dextromethorphan Abuse S. 2237, S. 2274, S. 1378, H.R. 970

Client expense: $110,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

S. 2274, Dextromethorphan Abuse Reduction Act of 2007, proposed scheduling of unfinished Dextromethophan as a Schedule V product under the Controlled Substances Act and mandates restriction for the sale of retail products which contain Dextromethorphan. S. 2237, Crime Control and Prevention Act of 2007, Subtitle B containing the same provisions as in the Dextromethorphan Abuse Reduction Act of 2007.

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S.2274, S.1378, H.R.970; Seeking increased restrictions on sale of Dextromethorphan, including prohibition of internet sale of bulk Dextromethorphan and under age 18 restrictions.

Client expense: Not reported · Firm income: Not reported

S.2274, S.1378, H.R.970; Seeking increased restrictions on sale of Dextromethorphan, including prohibition of internet sale of bulk Dextromethorphan and under age 18 restrictions.

Client expense: Not reported · Firm income: Not reported

S. 2274 - Dextromethorphan Abuse Reduction Act of 2007 relates to scheduling of certain drugs and mandated age restrictions for sale of certain retail drugs. S. 2237 - Crime Control & Prevention Act of 2007, Subtitle B containing the same provisions as in the Dextromethorphan Abuse Reduction Act of 2007.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 1276/H.R. 2747 the "Methamphetamine Production Prevention Act of 2007" regarding establishment of grant programs to facilitate the creation of methamphetamine precursor electronic logbook system; S. 2274 the "Dextromethrophan Abuse Reduction Act of 2007" regarding limiting sales of dextromethorphan to those 18 and over; S. 2470 the "Dehydroepiandrosterone Abuse Reduction Act of 2007" regarding limiting the sales of dehydroepiandrosterone to those 18 and over;

Client expense: $580,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

HR 970, S 1378, S 2237, S 2274 -- Medicine Abuse

Client expense: $244,322 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Proposed restrictions/scheduling of bulk Dextromethorphan - H.R. 970 Dextromethorphan Abuse Reduction Act - S. 2274 Crime Control & Prevention Act of 2007 - S. 2237

Client expense: Not reported · Firm income: $40,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE